CAR T-cell Therapy Articles

Tisagenlecleucel Responses in Pediatric ALL Sustained With Longer Follow-up
At a median follow-up of 13.1 months, tisagenlecleucel (Kymriah) induced an overall remission rate of 81% in children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
Locke Highlights Axi-Cel/Atezolizumab Data in DLBCL
Frederick L. Locke, MD, discusses the initial data for axicabtagene ciloleucel (axi-cel; Yescarta) plus atezolizumab (Tecentriq) in diffuse large B-cell lymphoma, and reflected on the long-term survival data from the ZUMA-1 trial.
ASCO Names CAR T-Cell Therapy as Cancer Advance of the Year
The annual update on oncology treatment highlights the most impactful clinical cancer research and policy developments over the past year in CAR T-cell therapy.
Liso-Cel Highly Active in Relapsed/Refractory DLBCL
David G. Maloney, MD, PhD, discusses the promise of lisocabtagene maraleucel in patients with diffuse large B-cell lymphoma.
CAR T-Cell Therapy Shows Promise in Relapsed/Refractory Myeloma
Jesus Berdeja, MD, discusses ongoing research with bb2121 in patients with relapsed/refractory myeloma.
CAR T-Cell Therapy an Emerging Explosion in Myeloma Paradigm
Nina Shah, MD, discusses immunotherapy and cellular treatments moving fast through the multiple myeloma pipeline, and the hope for CAR T-cell therapy to move up to earlier lines of treatment.
Considerations for CAR T-Cell Therapy in NHL
Babis Andreadis, MD, discusses the successes seen with CAR T-cell development in the past year and the use of CAR T-cell therapy in patients with NHL.
Beyond CARs: New T-Cell Strategies Take Center Stage
Recent advances in the understanding of the immune system are paving the way for new and effective approaches to treating cancer.
The FDA has granted a priority review to the CAR T-cell therapy tisagenlecleucel for adult patients with relapsed/refractory DLBCL who are ineligible for or relapse after autologous stem cell transplant. 
 
Axi-Cel Plus Atezolizumab Active, Safe in DLBCL
The combination of the CAR T-cell therapy axicabtagene ciloleucel and the PD-L1 inhibitor atezolizumab was highly active with a manageable safety profile in patients with refractory DLBCL enrolled in the phase I/II ZUMA-6 trial.
Publication Bottom Border
Border Publication
x